The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Regulatory aspects on nanomedicines
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Understanding biophysicochemical interactions at the nano–bio interface
Nel, A. E., Mädler, L., Velegol, D., Xia, T., Hoek, E. M. V., Somasundaran, P., Klaessig, F., Castranova, V., & Thompson, M. (2009) · Nature Materials · doi:10.1038/nmat2442 · Cited by 7,083
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Impact of Nanotechnology on Drug Delivery
Farokhzad, O. C., & Langer, R. (2009) · ACS Nano · doi:10.1021/nn900002m · Cited by 3,348
Applications of Carbon Nanotubes in Drug Delivery
Kaur, J., Gill, G. S., & Jeet, K. (2019) · Characterization and Biology of Nanomaterials for Drug Delivery · doi:10.1016/b978-0-12-814031-4.00005-2 · Cited by 2,019
Nanotechnology in concrete – A review
Sanchez, F., & Sobolev, K. (2010) · Construction and Building Materials · doi:10.1016/j.conbuildmat.2010.03.014 · Cited by 1,834
Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791
The emerging nanomedicine landscape
Wagner, V., Dullaart, A., Bock, A.-K., & Zweck, A. (2006) · Nature Biotechnology · doi:10.1038/nbt1006-1211 · Cited by 1,630
The big picture on nanomedicine: the state of investigational and approved nanomedicine products
Etheridge, M. L., Campbell, S. A., Erdman, A. G., Haynes, C. L., Wolf, S. M., & McCullough, J. (2013) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2012.05.013 · Cited by 1,088
Biomedical applications of functionalised carbon nanotubes
Bianco, A., Kostarelos, K., Partidos, C. D., & Prato, M. (2005) · Chemical Communications · doi:10.1039/b410943k · Cited by 1,086
Nanomedicine(s) under the Microscope
Duncan, R., & Gaspar, R. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200394t · Cited by 981
Self-citation
Cited by
Nano based drug delivery systems: recent developments and future prospects
Patra, J. K., Das, G., Fraceto, L. F., Campos, E. V. R., Rodriguez-Torres, M. D. P., Acosta-Torres, L. S., Diaz-Torres, L. A., Grillo, R., Swamy, M. K., Sharma, S., et al. (2018) · Journal of Nanobiotechnology · doi:10.1186/s12951-018-0392-8 · Cited by 6,684
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Anselmo, A. C., & Mitragotri, S. (2016) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10003 · Cited by 1,321
“, study design and approval challenges).(11,12) This review focuses on the clinical translation of intravenously administered nanoparticles, with additional emphasis on the challenges faced by nanoparticles from a clinical and translational point of view.”
BackgroundNanomaterials for cancer therapy: current progress and perspectives
Cheng, Z., Li, M., Dey, R., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01096-0 · Cited by 1,168
Ghezzi, M., Pescina, S., Padula, C., Santi, P., Del Favero, E., Cantù, L., & Nicoli, S. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.02.031 · Cited by 1,135
Hua, S., de Matos, M. B. C., Metselaar, J. M., & Storm, G. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00790 · Cited by 1,048
Nanomedicine: Principles, Properties, and Regulatory Issues
Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00360 · Cited by 790
Lombardo, D., & Kiselev, M. A. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14030543 · Cited by 718
Current hurdles to the translation of nanomedicines from bench to the clinic
Đorđević, S., Gonzalez, M. M., Conejos-Sánchez, I., Carreira, B., Pozzi, S., Acúrcio, R. C., Satchi-Fainaro, R., Florindo, H. F., & Vicent, M. J. (2022) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01024-2 · Cited by 657
Self-citationProtein-Based Nanoparticles as Drug Delivery Systems
Hong, S., Choi, D. W., Kim, H. N., Park, C. G., Lee, W., & Park, H. H. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12070604 · Cited by 619
Foulkes, R., Man, E., Thind, J., Yeung, S., Joy, A., & Hoskins, C. (2020) · Biomaterials Science · doi:10.1039/d0bm00558d · Cited by 568
Nanoparticles in Daily Life: Applications, Toxicity and Regulations
Gupta, R., & Xie, H. (2018) · Journal of Environmental Pathology, Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2018026009 · Cited by 553
Kus-Liśkiewicz, M., Fickers, P., & Ben Tahar, I. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222010952 · Cited by 404
Nanoparticle-based drug delivery systems: a commercial and regulatory outlook as the field matures
Ragelle, H., Danhier, F., Préat, V., Langer, R., & Anderson, D. G. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2016.1244187 · Cited by 390
Advances in Nanotechnology for Enhancing the Solubility and Bioavailability of Poorly Soluble Drugs
Liu, Y., Liang, Y., Yuhong, J., Xin, P., Han, J. L., Du, Y., Yu, X., Zhu, R., Zhang, M., Chen, W., et al. (2024) · Drug Design, Development and Therapy · doi:10.2147/dddt.s447496 · Cited by 365
BCS class IV drugs: Highly notorious candidates for formulation development
Ghadi, R., & Dand, N. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.01.014 · Cited by 361
Hydroxyapatite: A journey from biomaterials to advanced functional materials
Mondal, S., Park, S., Choi, J., Vu, T. T. H., Doan, V. H. M., Vo, T. T., Lee, B., & Oh, J. (2023) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2023.103013 · Cited by 344
Immune-mediated approaches against COVID-19
Florindo, H. F., Kleiner, R., Vaskovich-Koubi, D., Acúrcio, R. C., Carreira, B., Yeini, E., Tiram, G., Liubomirski, Y., & Satchi-Fainaro, R. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0732-3 · Cited by 338
Self-citationNanotechnology in healthcare, and its safety and environmental risks
Ma, X., Tian, Y., Yang, R., Wang, H., Allahou, L. W., Chang, J., Williams, G., Knowles, J. C., & Poma, A. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02901-x · Cited by 332
PEGylated Lipid Nanoparticle Formulations: Immunological Safety and Efficiency Perspective
Tenchov, R., Sasso, J. M., & Zhou, Q. A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00174 · Cited by 313
Nanotechnology: A Promising Approach for Delivery of Neuroprotective Drugs
Naqvi, S., Panghal, A., & Flora, S. J. S. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00494 · Cited by 305
Desai, N., Rana, D., Patel, M., Bajwa, N., Prasad, R., & Vora, L. K. (2025) · Small · doi:10.1002/smll.202502315 · Cited by 295
Liposome: composition, characterisation, preparation, and recent innovation in clinical applications
Ahmed, K. S., Hussein, S. A., Ali, A. H., Korma, S. A., Lipeng, Q., & Jinghua, C. (2019) · Journal of Drug Targeting · doi:10.1080/1061186x.2018.1527337 · Cited by 294
Sivadasan, D., Sultan, M. H., Madkhali, O., Almoshari, Y., & Thangavel, N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081291 · Cited by 288
Inorganic nanoparticles in clinical trials and translations
Huang, H., Feng, W., Chen, Y., & Shi, J. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100972 · Cited by 283
Ali, E. S., Sharker, S. M., Islam, M. T., Khan, I. N., Shaw, S., Rahman, M. A., Uddin, S. J., Shill, M. C., Rehman, S., Das, N., et al. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.011 · Cited by 267
Padrela, L., Rodrigues, M. A., Duarte, A., Dias, A. M. A., Braga, M. E. M., & de Sousa, H. C. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.07.010 · Cited by 262
Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities
Agrahari, V., & Agrahari, V. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.01.047 · Cited by 253
Domingues, C., Santos, A., Alvarez-Lorenzo, C., Concheiro, A., Jarak, I., Veiga, F., Barbosa, I., Dourado, M., & Figueiras, A. (2022) · ACS Nano · doi:10.1021/acsnano.2c00128 · Cited by 235
Metadata
- Authors
- Sainz, V., Conniot, J., Matos, A. I., Peres, C., Zupanǒiǒ, E., Moura, L., Silva, L. C., Florindo, H. F., & Gaspar, R. S.
- Venue
- Biochemical and Biophysical Research Communications
- Publisher
- Elsevier BV
- Published
- 2015-12
- Volume
- 468
- Issue
- 3
- Pages
- 504-510
- ISSN
- 0006-291X (ISSN-L)
- OpenAlex
- W1088146625
- Cited by
- 417
- References
- 41
- FWCI
- 7.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.